78. Hypopituitarism Clinical trials / Disease details
Clinical trials : 494 / Drugs : 385 - (DrugBank : 49) / Drug target genes : 44 - Drug target pathways : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00133354 (ClinicalTrials.gov) | November 2001 | 19/8/2005 | Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys | Double-blind Trial Investigating the Safety and Efficacy of the Inhibitor Anastrozole (ARIMIDEX) in Delaying Epiphyseal Fusion and Increasing Height Potential of Adolescent Males With Growth Hormone (GH) Deficiency | Hypopituitarism | Drug: Arimidex (Anastrozole);Drug: Placebo;Drug: Growth Hormone | Nemours Children's Clinic | AstraZeneca;Genentech, Inc.;EMD Serono | Completed | 11 Years | 18 Years | Male | 53 | Phase 2/Phase 3 | United States |